Getting Ahead of Nonalcoholic Steatohepatitis (NASH)

To participate in this activity, please:

Nonalcoholic fatty liver disease, more recently known as metabolic dysfunction-associated steatotic liver disease (MASLD), affects nearly 1 in 4 adults. Left untreated, patients with MASLD can suffer metabolic, cardiovascular, and liver-related complications including cirrhosis and death. Noninvasive tests are widely available to screen patients at risk of MASLD. Weight loss and cardiovascular risk reduction, followed by directed pharmacotherapy, are the mainstays of treatment.In this 1-hour journal-style review article, supplemented with video clips of key concepts, Drs. Jay Shubrook and Arun Sanyal provide their insights about the primary care identification, diagnosis, and treatment of patients with MASLD.

Course Credit:

1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour
0.5 Pharmacology Hours


Opens: 2024-01-26
Closes: 2025-02-01

Target Audience:

The primary target audience includes healthcare professionals who care for patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with a focus on primary care providers (MD, PA, and NP).

This program is supported by an educational grant provided by Novo Nordisk.


In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 ANCC contact hour, including 0.5 pharmacology hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Heather Jimenez, MSN, FNP-C (Nurse Reviewer)
No significant relationships to disclose.

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Michael Smith, PharmD, BCPS (Medical Writer)

Consultant: Wolters-Kluwer

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Arun J. Sanyal, MD

    Director,  Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
    Interim Chair, Division of Gastroenterology, Hepatology, and Nutrition
    Virginia Commonwealth University Medical Center
    Richmond, Virginia

  • Jay H. Shubrook, DO

    Director of Clinical Research and Diabetes Services
    TUCA/Solano County Family Health Services
    Professor, and Interim Chair
    Department of Clinical Sciences and Community Health
    Touro University California College of Osteopathic Medicine
    Vallejo, California

Learning Objectives

  • Recognize patients at high risk for developing NASH.
  • Determine the utility of noninvasive tests and biomarkers for routine clinical practice to diagnose, stage, and monitor patients with NASH.
  • Apply the guideline-recommended therapies that target associated comorbidities earlier in the course of disease for patients with NASH as recommended by AASLD.
  • Formulate multidisciplinary strategies to improve the early diagnosis and treatment of patients with NASH.

Faculty Disclosures

Arun J. Sanyal, MD

Consultant: Akero, Alnylam, AstraZeneca, Biocellvia, Boehringer Ingelheim, Eli Lilly, FibroNest, Fractyl, Genentech, Gilead, GlaxoSmithKline, HistoIndex, Intercept, Inventiva, Madrigal, Merck, NorthSea, Novo Nordisk, Novartis, Path-AI, Pfizer, Regeneron, Roche, Takeda, TARGET PharmaSolutions, Terns

Stock Options: Durect, Genfit, HemoShear, Inversago, Tiziana

Jay H. Shubrook, DO

Advisory Board: AstraZeneca, Bayer, Eli Lilly, Nevro, Novo Nordisk

Consultant: Abbott